My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Celcuity Inc. - Common Stock (NQ:CELC)

97.50 +3.50 (+3.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

August 03, 2022

Via ACCESSWIRE

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 18, 2022

Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million.

Via Benzinga

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

July 18, 2022

MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today...

From Celcuity Inc.

Via AccessWire

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022 ↗

March 24, 2022

Via Benzinga

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

May 26, 2022

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Recap: Celcuity Q1 Earnings ↗

May 16, 2022

Celcuity (NASDAQ:CELC) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity beat estimated earnings by...

Via Benzinga

Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

May 16, 2022

- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast...

From Celcuity Inc.

Via AccessWire

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

Recap: Celcuity Q4 Earnings ↗

March 23, 2022

Celcuity (NASDAQ:CELC) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity...

Via Benzinga

Preview: Celcuity's Earnings ↗

March 22, 2022

Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Via Benzinga

Celcuity Inc. Announces $100 Million Private Placement

May 16, 2022

Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a...

From Celcuity Inc.

Via AccessWire

Earnings Preview For Celcuity ↗

May 13, 2022

Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will report...

Via Benzinga

Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

May 09, 2022

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

April 05, 2022

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 24, 2022

On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market...

Via Benzinga

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

March 23, 2022

- Finalized pivotal Phase 3 trial design following formal meetings with FDA - Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer - Presented updated Phase 1b data...

From Celcuity Inc.

Via AccessWire

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

Earnings Scheduled For March 23, 2022 ↗

March 23, 2022

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 17, 2022

Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...

Via Benzinga

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

March 16, 2022

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

March 02, 2022

MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity ↗

January 18, 2022

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program...

Via Benzinga

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update

January 18, 2022

- FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients - On track to finalize Phase 3...

From Celcuity Inc.

Via AccessWire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 22, 2021

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.